uniQure N.V. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount
uniQure N.V. (QURE) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount of $5.60 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-02-27.
Financial Statements › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost · last filed 2025-02-27
- uniQure N.V. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2024 was $5.60M, a 37.78% decline from fiscal 2023.
- uniQure N.V. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2023 was $9.00M, a 5.88% increase from fiscal 2022.
- uniQure N.V. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2022 was $8.50M, a 26.87% increase from fiscal 2021.
- uniQure N.V. effective income tax rate reconciliation, nondeductible expense, share-based payment arrangement, amount for fiscal 2021 was $6.70M, a 15.52% increase from fiscal 2020.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-based Payment Arrangement, Amount 12 month |
|---|---|
| 2024-12-31 | $5.60M 10-K · filed 2025-02-27 |
| 2023-12-31 | $9.00M 10-K · filed 2025-02-27 |
| 2022-12-31 | $8.50M 10-K · filed 2025-02-27 |
| 2021-12-31 | $6.70M 10-K · filed 2024-02-28 |
| 2020-12-31 | $5.80M 10-K · filed 2023-02-27 |
| 2019-12-31 | $4.40M 10-K · filed 2022-02-25 |
| 2018-12-31 | $2.70M 10-K · filed 2021-03-01 |
| 2017-12-31 | $2.50M 10-K · filed 2020-03-02 |
| 2016-12-31 | $1.60M 10-K · filed 2019-02-28 |
| 2015-12-31 | $2.90M 10-K · filed 2018-03-14 |
| 2014-12-31 | $2.10M 10-K · filed 2017-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |